Bausch + Lomb Expands AMD Portfolio with PreserVision AREDS3 Launch
Event summary
- Bausch + Lomb launched PreserVision AREDS3 eye vitamins in the U.S. on May 19, 2026.
- The new formula combines AREDS2 nutrients with a proprietary B-vitamin complex.
- PreserVision AREDS3 is designed to support earlier stages of age-related macular degeneration (AMD).
- The product is now available nationwide at major retailers including Amazon, Target, Walgreens, and Walmart.
The big picture
Bausch + Lomb's launch of PreserVision AREDS3 reflects a strategic shift towards earlier intervention in AMD management, leveraging decades of research on B vitamins. This move positions the company to address a broader patient population, potentially expanding its market reach in the competitive eye health sector. The inclusion of a proprietary B-vitamin complex differentiates the product from existing AREDS2-based formulations, aligning with evolving scientific evidence on nutritional support for macular health.
What we're watching
- Market Penetration
- Whether Bausch + Lomb can capture a significant share of the earlier-stage AMD nutritional support market.
- Clinical Validation
- The pace at which long-term clinical trials will validate the efficacy of the B-vitamin complex in PreserVision AREDS3.
- Competitive Response
- How competitors will react to the expanded PreserVision portfolio, particularly in the nutritional support segment.
Related topics